Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 147 points (1.0%) at 15,587 as of Thursday, Feb. 6, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,311 issues advancing vs. 626 declining with 152 unchanged. The Drugs industry currently sits up 0.8% versus the S&P 500, which is up 1.0%. Top gainers within the industry include Biogen Idec ( BIIB), up 1.9%, Shire ( SHPG), up 1.8%, Novo Nordisk A/S ( NVO), up 1.7%, GlaxoSmithKline ( GSK), up 0.9% and Johnson & Johnson ( JNJ), up 0.9%. TheStreet would like to highlight 4 stocks pushing the industry lower today: 4. Sanofi ( SNY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Sanofi is down $0.88 (-1.8%) to $47.41 on heavy volume. Thus far, 2.0 million shares of Sanofi exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $47.06-$47.50 after having opened the day at $47.08 as compared to the previous trading day's close of $48.29. Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $129.4 billion and is part of the health care sector. Shares are down 10.0% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.